Ubicom Holdings. Inc. · TSE:3937

Ubicom — FY2026 Q2 Earnings Presentation

39 slides from Ubicom's earnings presentation, Nov 12, 2026

  1. Slide 1: FY2026 Q2 Financial Results Materials

    Ubicom Holdings, Inc. (Standard Market of TSE: 3937) FY2026 Q2 Financial Results Materials November 12, 2026 (Note) FY2026 (fiscal year ending March 31, 2027)

  2. Slide 2: Table of Contents

    Table of Contents 01 Highlights of Consolidated Financial Results for FY2026 Q2 P.3 02 Overview of Consolidated Financial Results (P/L) for FY2026 Q2 P.4 03 Medical Business P.5 04 AI Technology Strategy Business P.14 05 Dividend Policy P.23 06 Business Forecast & Performance Trends P.25 07 Appendix

  3. Slide 3: Highlights of Consolidated Financial Results for FY2026 Q2

    Highlights of Consolidated Financial Results for FY2026 Q2  Company performance: In FY2026 Q2, sales, operating income, ordinary income, and interim net income all exceeded the same period of the previous year, setting new second-quarter records. Progress toward the full-year plan remained solid. 

  4. Slide 4: Overview of Consolidated Financial Results (P/L) for FY2026 Q2

    Overview of Consolidated Financial Results (P/L) for FY2026 Q2 Sales increased by 18.8% year on year and operating income by 19.9%, reflecting steady growth. Progress toward the full-year business forecast remained solid: 47.9% for sales, 52.8% for operating income, 54.6% for ordinary income, and 54

  5. Slide 5: Medical Business

    Medical Business 5

  6. Slide 6: Medical Business: Overview by Segment for FY2026 Q2

    Medical Business: Overview by Segment for FY2026 Q2 (Business Performance) As a healthcare platform provider, the Company continues to steadily build its recurring revenue base through its Mighty series and Insurance Knowledge Platform, while expanding its revenue scale through M&A. As a result, bot

  7. Slide 7: Mighty Series User Base Trend

    AI×Subscription Model: Mighty Series User Base Trend Healthcare DX investment accelerated following physician work-style reforms and medical fee revisions in April 2024, driving steady growth in new users alongside existing customer migration. Hospitals (Unit: facilities) 22,912 23,453 Clinics 21,94

  8. Slide 8: Improving Profitability Through Group-Wide Cross-Selling and Stronger Direct Sales

    Improving Profitability Through Group-Wide Cross-Selling and Stronger Direct Sales Radianceware’s earnings contribution, combined with greater use of the three Group companies’ customer bases, products, and sales capabilities, is strengthening the Group’s earnings base. Continued M&A will accelerate

  9. Slide 9: Strategy to Maximize Radianceware's Profitability

    Strategy to Maximize Radianceware’s Profitability Radianceware’s Growth Opportunities Radianceware’s Key Challenges Strong Demand for Healthcare IT Systems Driven Tripling headcount through recruitment and reallocation to address by Medical DX Vision 2030 *1. strong demand and strengthen consultativ

  10. Slide 10: AI x High-Margin Recurring Core Solutions: the Mighty Series

    AI × High-Margin Recurring Core Solutions: the “Mighty” Series Cross-selling the Mighty series to deliver revenue growth and cost savings for medical institutions. Leveraging these improvements to strengthen sales proposals for EMR and related systems. Driving Solutions Through the Mighty series Key

  11. Slide 11: Insurance Knowledge Platform: Driving DX in the Insurance Industry

    Insurance Knowledge Platform: Driving DX in the Insurance Industry A business support platform streamlining benefit claims assessment for life insurers. A Win-Win-Win Solution Driving Insurance Medical Data × Proprietary AI Recurring Revenue Growth Through Industry DX Through Medical Data × AI Advant

  12. Slide 12: Long-Term Strategy: M&A Strategy

    Long-Term Strategy: M&A Strategy (Nationwide Distributor Acquisitions) From 2025 through 2030, the Company will pursue M&A to maximize the profitability of the Medical Business. By building its own nationwide direct sales network and direct customer relationships, the Group aims to capture more reve

  13. Slide 13: Scenarios for Medium to Long-Term Growth in the Medical Business

    Scenarios for Medium to Long-Term Growth in the Medical Business Achieving sustainable mid- to long-term growth through both organic growth in stable recurring revenues and inorganic growth through M&A. Positioning M&A as a strategic investment to expand business scale and enhance future earnings ca

  14. Slide 14: AI Technology Strategy Business

    AI Technology Strategy Business 14

  15. Slide 15: AI Technology Strategy Business: Overview by Segment for FY2026 Q2

    AI Technology Strategy Business: Overview by Segment for FY2026 Q2 (Business Performance) Profitability improved, driven by revenue growth at the Philippine subsidiary, cost structure reforms, and a stronger AI-driven development framework. Both sales and operating income increased year on year, wit

  16. Slide 16: Philippine Subsidiary: Evolving to a Global AI Profit Center

    Philippine Subsidiary: Evolving from a “Development Base” to a “Global AI Profit Center”  The Philippine subsidiary achieved record high sales and operating income.  Under the Go Global strategy, the expansion of direct-contract projects, including AI-related projects with leading U.S. healthcare

  17. Slide 17: Overview of the Business Model Transformation to an AI-Driven Development Framework

    Overview of the Business Model Transformation to an AI-Driven Development Framework AI Technology Strategy Business-Growth Strategy Overview, FY2026 Onward  The Company is advancing its transition from a man-month-based model dependent on “headcount × time” to an AI-driven development framework lev

  18. Slide 18: Business Model Transformation through AI-Driven Development

    Business Model Transformation through AI-Driven Development Initiative Content Phase Progress 【FY2025 Q3 – Q4】 • Analyzed watsonx*1 assets using the Company’s technical and English-language Develop AI-native engineers / Expand AI Building the AI Completed capabilities to build a delivery framework p

  19. Slide 19: AI Projects: Strengthening the Strategic Partnership with Kobelco Systems

    AI Projects: Horizontal Deployment — Strengthening the Strategic Partnership with Kobelco Systems The Company is expanding the horizontal deployment of its AI-driven development technologies and knowledge, strengthening its strategic partnership with Kobelco Systems to accelerate business growth and

  20. Slide 20: Market Opportunities: Growing Demand for Modernization

    Market Size of the Modernization Field and the Company’s Competitive Advantages Going forward, the Company will leverage “IBM Bob” and “ALSEA” to modernize existing systems and accelerate the expansion of its AI-driven development business. The Company’s Competitive Advantages As IBM's strategic par

  21. Slide 21: Overview of AI Use Cases (by Industry)

    Overview of AI Use Cases (by Industry) AI is utilized across areas including the upstream phase (requirements definition), and cross-industry AI adoption is expanding. With the establishment of the AI-driven development framework complete, the Company is accelerating the creation of high value-added

  22. Slide 22: Target Domains for Building an AI-Driven Development Framework

    Target Domains for Building an AI-Driven Development Framework The generative AI market is expected to expand over the medium to long term both in Japan and worldwide, with growing demand for AI utilization across industrial domains such as finance, manufacturing, healthcare, and social infrastructu

  23. Slide 23: Dividend Policy

    Dividend Policy 23

  24. Slide 24: A dividend policy enabling shareholders to directly benefit from growth

    A dividend policy enabling shareholders to directly benefit from growth 【Dividend Policy】 ① Although FY2025 results fell short of the initial forecast due to temporary impacts from growth investments and business portfolio optimization, the Medical Business continued to strengthen its earnings found

  25. Slide 25: Business Forecast & Performance Trends

    Business Forecast & Performance Trends 25

  26. Slide 26: Business Forecast and Financial Performance Trend

    Business Forecast and Financial Performance Trend [Business Forecast Assumptions] • For FY2026 forecast, we expect further expansion of the revenue base in the Medical Business and contributions from newly acquired subsidiaries through M&A. • The forecast incorporates higher depreciation expenses re

  27. Slide 27: Business Forecast and Financial Performance Trend: Key Strategic Initiatives

    Business Forecast and Financial Performance Trend 【Key Strategic Initiatives】 ① Continuous execution of M&A strategy The Company will continuously promote M&A to expand its revenue base and accelerate the accumulation of recurring income. Early realization of synergies will be achieved through post-

  28. Slide 28: Appendix

    Appendix 28

  29. Slide 29: Our Business Model: Resolving Social Issues in Japan

    Our Business Model: A Model for Resolving Social Issues in Japan, A Developed Country Facing Challenges 01 Medical Business 02 AI Technology Strategy Business Reforming the workstyle of Against the backdrop of an medical professionals anticipated shortage of 3.26 million Improving the profitability

  30. Slide 30: Medical Business: The Tailwind Created by Social Issues and Policy Measures

    Medical Business: The Tailwind Created by Social Issues and Policy Measures (Market Environment) Increasing deficits of medical institutions and social security spending cuts: three growth opportunities arising from structural challenges Increasing deficits in The coverage rate of EMR is Business fi

  31. Slide 31: Medical Business: Impact of M&A Strategy Execution (KPI Changes)

    Medical Business: Impact of M&A Strategy Execution (KPI Changes) Over the five years from 2025 to 2030, we will execute 8 to 10 M&A deals with the aim of increasing the Group's direct sales ratio. <Factors contributing to LTV *1 improvement> Content Measurement Details Increase of ①Inclusion of agen

  32. Slide 32: Medical Business: Revenue Recognition Methods (Billing Methods)

    Medical Business: Revenue Recognition Methods (Billing Methods) License revenue for the Mighty series is recognized on a straight-line basis. With the increase in contract numbers, sales steadily accumulate on a monthly basis, achieving revenue stabilization. Furthermore, the AI × subscription model

  33. Slide 33: M&A Strategy Phase 2: Maximizing Medical Business Profitability

    M&A Strategy Phase 2: Maximizing Medical Business Profitability Radianceware Financial Performance Trend Over the Quantitative Evaluation and Investment Past Three Years Decision for This M&A (Unit: million yen) Sales 2 consecutive years of ① Comparison with Target Payback Period revenue and profit

  34. Slide 34: Launch of New Product MightyChecker Cloud X

    Launch of New Product “MightyChecker® Cloud X” N e x t - g e n e r a t i o n c l o u d - b a s e d me d i ca l c l a i ms i n s p e c t i o n s o f t w a re Launch of New Product “MightyChecker® Cloud X” (April 2026) Features of MightyChecker® Cloud X Targets Improved Operational Efficiency Migratio

  35. Slide 35: Promotion of Group Businesses Based on Social Significance

    Promotion of Group Businesses Based on Social Significance Provision of solutions that are beneficial to three key areas: pressing need for workstyle reforms for medical doctors, improvement Growing demand due to the reassessment of in management of medical institutions, and offshore development par

  36. Slide 36: ESG: For sustainable growth of business, society, and client companies

    ESG:For sustainable growth of business, society, and client companies Goals Concrete Activities Related SDGs ・To make the electric power consumed E ・To reduce CO2 emissions at the head office 100% derived from renewable energy ・Global partnership ・Investment in equipment of subsidiaries in the Phili

  37. Slide 37: Corporate Profile

    Corporate Profile ■Corporate name: Ubicom Holdings, Inc. (Standard Market of TSE: 3937) ■Strategic markets: healthcare, finance, public services, automobiles, manufacturing, robotics, real estate, energy, etc. ■Business description: AI Technology Strategy Business In order to solve the problem of sh

  38. Slide 38: Cautionary Note Regarding Forward-Looking Statements

    Cautionary Note Regarding Forward-Looking Statements  The materials and information provided in this announcement include forward-looking statements based on our current estimates and expectations at this point of time.  Such forward-looking statements are subject to various risks and uncertaintie

  39. Slide 39: Holdings, Inc.

    Holdings, Inc. = fe) Q Q =) 39

Ubicom Holdings — FY2026 Q2 Earnings Presentation on 6ix